

8/1/2011; page 1

Suggested Formula	Clindamycin Hydrochloride 40.72 mg Oral Capsules (Powder Blend, 100 x Size # 1 Capsule)	FIN	F 001 928v2
----------------------	--	-----	-------------

<u>NOTE</u>: Clindamycin Hydrochloride 40.72 mg is equivalent to Clindamycin 37.5 mg.

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Clindamycin Hydrochloride (Dehydrated), USP	4.072	g				
Lactose (Monohydrate), NF	TBD					
Sodium Chloride, USP	As required		(0			

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information	
Narrow Therapeutic Index:	Clindamycin Hydrochloride (Dehydrated)
Suggested Preparatory Guidelines	
Non-Sterile Preparat	ion Sterile Preparation
<u>Processing Error /</u> <u>Testing Considerations</u> :	To account for processing error considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.
	Clindamycin Hydrochloride (Dehydrated) has a Narrow Therapeutic Index. This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



8/1/2011; page 2

Suggested Formula	Clindamycin Hydrochloride 40.72 mg Oral Capsules (Powder Blend, 100 x Size # 1 Capsule)	FIN	F 001 928v2
----------------------	--	-----	-------------

SUGGESTED PREPARATION (for 100 Size #1 Capsules)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) :	Processing Error	Qty. to measure
Clindamycin Hydrochloride (Dehydrated), USP	4.072	g			
Lactose (Monohydrate), NF	TBD				
Sodium Chloride, USP	As required		8		

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

	Preparatory Instruction						
1.	Lactose (Monohydrate) requirements for 100 x size #1 capsules						
	A. Calculate the amount of Lactose (Monohydrate) required for the batch. Refer to attached appendix for details.						
2.	Powder preparation:						
	A. Triturate the Clindamycin Hydrochloride to form a fine, homogeneous powder.						
	B. By geometric addition, combine and mix the following ingredients together:						
	-Fine, homogeneous powder (Step 2A)						
	-Lactose (Monohydrate) (Quantity determined in appendix (I))						
3.	Product transfer:						
	Fill each of 100 Size #1 capsules with the powder blend (Step 2B). Close each capsule tightly.						
	Clean each capsule by placing the capsules in a container filled with Sodium chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium chloride to pass through. Finally, roll the capsules on a cloth-covered surface.						
4.	Validation technique (average capsule weight):						
	The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight, in accordance to USP 795 guidelines. The theoretically calculated weight can be determined by adding the amount in appendix (\mathbf{G}) + 0.04072 g together.						
5.	Product transfer:						
	Transfer the final product into the specified dispensing container (see "Packaging Requirements").						



8/1/2011; page 3

Suggested Formula	Clindamycin Hydrochloride 40.72 mg Oral Capsules (Powder Blend, 100 x Size # 1 Capsule)	FIN	F 001 928v2
----------------------	--	-----	-------------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		6 months, as per USP.	Packaging Requirements		Tightly closed vials.		
	1	Use as directed. Do not exceed dose.	d prescribed	4	Keep in a dry place.		
Auxiliary	2	Keep out of reach of children.		5	Cap tightly after use.		
Labels	3	Keep at room temperature (20°C	C − 23°C).	6	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.		
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.						
Patient Instructions							

REFERENCES

1.	Capsules. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 91.					
2.	Dalacin C. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2005. 618.					
3. Lactose. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 4 th Edition. American Pharmaceutical Asso 2003: 323.						
4.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 556.					
5.	Clindamycin Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 34th Edition</i> . London, England: The Pharmaceutical Press; 2005: 194.					
6.	Clindamycin Hydrochloride (Monograph). In: O'Neil MJ. <i>The Merck Index 13th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 411.					
7.	Clindamycin Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> , 3 rd Edition. American Pharmaceutical Association; 2005: 108.					
8.	Clindamycin Hydrochloride (Monograph). <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 493.					
9.	USP <795>. United States Pharmacopeia XXVIII / National Formulary 23. Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 2457.					
10.	Clindamycin Systemic. Thomson Micromedex. USP DI – Drug Information for the Health Care Professional, 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 904.					

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



8/1/2011; page 1

Calculating the quantity of excipient required for the batch Appendix Procedure 1. **Capsule filling:** a. For each ingredient powder below, determine the average capsule fill weight by filling and weighing five TARED CAPSULES. Do not forget to divide the total weight by 5 to obtain an average capsule fill weight. Also, triturate the ingredient powder first if required in formulation Plug each amount into Step 2, column B. 2. **Volume Percent Occupied:** Column B Column C Column A Quantity Required Average capsule A/B x 100 equals Ingredients per capsule fill weight percent filled 0.04072 g a. Clindamycin Hydrochloride % g b. Lactose (Monohydrate) g c. Total (add column C together) % (D) 3. **Calculate the quantity of Lactose (Monohydrate) required for the batch:** a. Percent of Lactose (Monohydrate) required = 100% - (D)% (E) _____g (F) b. Average capsule fill weight of Lactose (Monohydrate) (from column B, Step 2b): c. Quantity of Lactose (Monohydrate) required per capsule = $[(E) \div 100 \times (F)]$ _____ g (G) d. Total quantity of Lactose (Monohydrate) required for the batch = 100 capsules \times (G) _____g (**H**) _____g (I) e. Total quantity of Lactose (Monohydrate) *plus* processing error = $(H) \times 1.05-1.09$

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.